Want to see GB:PYC full AI Analyst Report?
Top Page
Physiomics
(LSE:PYC)
Select Model
Select Model
Rating:53Neutral
Price Target:
0.48 p
▼(-7.50% Downside)
Action:Reiterated
Date:07/14/26
The overall score is held down primarily by weak financial performance, with persistent losses and worsening operating cash flows creating significant execution and funding risk despite strong top‑line growth and a debt‑free balance sheet. Technical indicators contribute a slightly positive but modest influence, reflecting neutral to mildly constructive price action without strong momentum. Valuation metrics, while based on negative earnings and no dividend, do not appear extreme, offering a moderate offset but not enough to outweigh the high‑risk financial profile. Together, these factors yield a cautious, slightly below‑average stock score.
Positive Factors
Low leverage / clean balance sheet
Having essentially zero reported debt provides durable financial flexibility and reduces near-term refinancing pressure. A clean leverage profile lets management prioritize operational progress and client wins without immediate debt service constraints, extending runway while pursuing growth.
Negative Factors
Persistent cash burn
Ongoing negative operating and free cash flow indicates the business is not yet self-funding and will likely require external capital if losses continue. Persistent cash burn elevates refinancing and dilution risk and constrains capacity to invest in growth or R&D without fresh funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / clean balance sheet
Having essentially zero reported debt provides durable financial flexibility and reduces near-term refinancing pressure. A clean leverage profile lets management prioritize operational progress and client wins without immediate debt service constraints, extending runway while pursuing growth.
Read all positive factors
Physiomics (PYC) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£2.38M
Dividend YieldN/A
Average Volume (3M)2.99M
Price to Earnings (P/E)―
Beta (1Y)0.57
Revenue Growth91.27%
EPS Growth60.98%
CountryUK
Employees10
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding453,208,700
10 Day Avg. Volume2,027,576
30 Day Avg. Volume2,992,536
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.60
Price to Sales (P/S)1.41
P/FCF Ratio-2.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Physiomics Business Overview & Revenue Model
Company Description
Founded in 2001 and headquartered in Oxford, UK, Physiomics Plc offers expert consulting services to pharmaceutical enterprises across the United Kingdom, the United States, and the European Union. The company's core specialization lies in outsour...
How the Company Makes Money
Physiomics makes money primarily by providing fee-for-service R&D support to external clients (typically biopharmaceutical companies, biotech firms, and academic or research organizations). Its core revenue stream is contract/service income from p...
Physiomics Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
65
Positive
Cash Flow
20
Very Negative
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 953.00K | 784.00K | 543.25K | 597.35K | 830.27K | 702.31K |
| Gross Profit | -543.08K | -435.08K | -677.43K | -581.62K | -429.01K | -365.79K |
| EBITDA | -553.33K | -448.21K | -659.80K | -561.57K | -347.84K | -324.52K |
| Net Income | -485.25K | -415.25K | -609.35K | -477.26K | -253.14K | -215.83K |
Balance Sheet | ||||||
| Total Assets | 558.00K | 892.03K | 422.60K | 674.39K | 1.12M | 1.32M |
| Cash, Cash Equivalents and Short-Term Investments | 257.00K | 461.24K | 191.07K | 416.59K | 687.67K | 1.04M |
| Total Debt | 0.00 | 0.00 | 3.83K | 7.35K | 0.00 | 0.00 |
| Total Liabilities | 165.00K | 199.85K | 140.08K | 142.67K | 140.61K | 157.57K |
| Stockholders Equity | 393.00K | 692.17K | 282.53K | 531.72K | 974.81K | 1.17M |
Cash Flow | ||||||
| Free Cash Flow | -469.08K | -550.08K | -565.44K | -271.50K | -358.62K | -48.65K |
| Operating Cash Flow | -464.14K | -546.14K | -548.13K | -264.86K | -349.25K | -32.50K |
| Investing Cash Flow | -4.41K | -3.41K | -15.21K | -6.22K | -9.37K | -16.15K |
| Financing Cash Flow | 456.73K | 819.73K | 337.83K | 0.00 | 2.85K | 44.24K |
Physiomics Technical Analysis
Positive
0.52
Price Trends
0.49
Positive
0.52
Negative
0.46
Positive
Market Momentum
0.02
Negative
53.65
Neutral
49.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:PYC, the sentiment is Positive. The current price of 0.52 is above the 20-day moving average (MA) of 0.51, above the 50-day MA of 0.49, and above the 200-day MA of 0.46, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 53.65 is Neutral, neither overbought nor oversold. The STOCH value of 49.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:PYC.
Physiomics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | £16.42M | -3.83 | -16.18% | ― | 13.04% | 15.88% | |
53 Neutral | £2.38M | -3.09 | -89.43% | ― | 91.27% | 60.98% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £5.05M | -1.68 | -37.30% | ― | ― | 85.56% | |
49 Neutral | £6.56M | -1.68 | -52.92% | ― | 34.02% | -93.85% | |
38 Underperform | £15.46M | -0.29 | -451.74% | ― | 33.37% | 86.41% | |
38 Underperform | £1.91M | -0.35 | -70.79% | ― | -36.97% | 62.76% |
* Healthcare Sector Average
GB:PYC
Physiomics
0.53
0.05
10.53%
GB:TCF
Evgen Pharma
0.19
-0.07
-26.00%
GB:IXI
IXICO plc
7.50
-4.00
-34.78%
GB:OPTI
OptiBiotix Health
6.35
-3.90
-38.05%
GB:OBD
Oxford BioDynamics
0.12
-0.34
-74.44%
GB:VAL
ValiRx plc
0.15
-0.53
-78.52%
Physiomics Corporate Events
Regulatory Filings and Compliance
Physiomics Director Increases Stake with New Share Purchase
Positive
Jul 14, 2026
Physiomics plc, a specialist in mathematical modelling and data-driven decision support for drug development, announced that executive director Ian Bagnall has increased his stake in the company. He purchased 1,111,111 ordinary shares at £0.0...
Other
Physiomics Director Increases Stake with 3 Million-Share Purchase
Positive
Jul 13, 2026
Physiomics plc, a specialist in modelling and simulation, biostatistics, data science and bioinformatics for drug development and personalised medicine, provides services that help pharmaceutical and biotech companies optimise research design and ...
Business Operations and StrategyFinancial Disclosures
Physiomics wins £200,000-plus contracts across biometrics and modelling services
Positive
Jul 8, 2026
Physiomics plc has secured a series of new and follow-on contracts worth more than £200,000, spanning its Biometrics and Modelling Simulation service lines. The awards include extensions to ongoing clinical development work with immunology a...
Business Operations and StrategyExecutive/Board Changes
Physiomics Names New COO to Drive Operational Scale and Growth
Positive
Jul 1, 2026
Physiomics plc, a mathematical modelling and data science consultancy serving the biotech and pharmaceutical sectors, provides model-informed drug development, biostatistics and bioinformatics services. Its proprietary Virtual Tumour platform and ...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Physiomics shifts board pay toward equity with new share and option awards
Positive
Jun 30, 2026
Physiomics has unveiled a revised director remuneration structure built around equity, announcing the conditional issue of 14,000,000 new ordinary shares to its chairman and two executive directors at 0.50 pence per share, subject to approval at t...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresShareholder Meetings
Physiomics builds record pipeline as new board drives cost savings and targets breakeven
Positive
Jun 26, 2026
Physiomics has reported strong operational progress, highlighting that it is currently building the largest commercial pipeline in its history, which it says underpins future growth and reinforces confidence in its market position. The board notes...
Business Operations and StrategyProduct-Related Announcements
Physiomics Showcases Hantavirus Modelling Framework to Expand Infectious Disease Capabilities
Positive
May 28, 2026
Physiomics has unveiled a new translational modelling framework for hantavirus, showcasing its ability to integrate in vitro antiviral screening, concentration–response modelling, pharmacokinetic simulations and mechanistic viral dynamics wi...
Business Operations and Strategy
Physiomics Wins £345,000 of New Drug Development Contracts
Positive
May 27, 2026
Physiomics plc has secured multiple new contracts in May worth over £345,000, spanning both new and follow-on engagements with UK and international biotechnology and oncology-focused organisations, including a NASDAQ-listed clinical-stage bio...
Business Operations and StrategyExecutive/Board Changes
Physiomics Extends CEO Peter Sargent’s Tenure Amid Strategic Transition
Positive
May 15, 2026
Physiomics plc has announced that CEO Peter Sargent has agreed to extend his current agreement and will remain in his role through June 2026, providing continuity as the company navigates a period of significant internal change. The board is in on...
Business Operations and StrategyExecutive/Board Changes
Physiomics appoints transformation specialist to steer leadership transition and growth strategy
Positive
May 12, 2026
Physiomics plc, a UK-based specialist in mathematical modelling, data science and biostatistics for drug development and personalised medicine, provides computational tools and bespoke models to help biotech and pharma companies de-risk decisions ...
Business Operations and StrategyExecutive/Board Changes
Physiomics’ New Board Launches Strategic Overhaul to Drive Growth and Discipline
Positive
May 8, 2026
Physiomics’ newly appointed board has launched a wide-ranging strategic review aimed at sharpening operational efficiency, strengthening commercial execution and driving long-term shareholder value. The company highlights underappreciated st...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.